MA33922B1 - Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a - Google Patents

Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Info

Publication number
MA33922B1
MA33922B1 MA35063A MA35063A MA33922B1 MA 33922 B1 MA33922 B1 MA 33922B1 MA 35063 A MA35063 A MA 35063A MA 35063 A MA35063 A MA 35063A MA 33922 B1 MA33922 B1 MA 33922B1
Authority
MA
Morocco
Prior art keywords
relates
patient
inhibitors
heteraromatic
formula
Prior art date
Application number
MA35063A
Other languages
Arabic (ar)
English (en)
Inventor
Ask Püschl
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mauro Marigo
Morten Langgård
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33922B1 publication Critical patent/MA33922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Valve Device For Special Equipments (AREA)

Abstract

La présente invention a pour objet des composés qui sont des inhibiteurs de l'enzyme PDE10A. La présente invention concerne une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un composé selon l'invention et un véhicule pharmaceutiquement acceptable. La présente invention concerne également des procédés pour la préparation des composés de formule I. La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble neurodégénératif comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule I. La présente invention concerne également une méthode de traitement d'un sujet souffrant d'une pharmacodépendance comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule I. La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble psychiatrique comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule I.
MA35063A 2009-12-17 2010-12-15 Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a MA33922B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28731509P 2009-12-17 2009-12-17
DKPA200901339 2009-12-17
PCT/DK2010/050341 WO2011072694A1 (fr) 2009-12-17 2010-12-15 Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Publications (1)

Publication Number Publication Date
MA33922B1 true MA33922B1 (fr) 2013-01-02

Family

ID=44246808

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35063A MA33922B1 (fr) 2009-12-17 2010-12-15 Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Country Status (36)

Country Link
US (2) US9096589B2 (fr)
EP (1) EP2513107B1 (fr)
JP (1) JP5901535B2 (fr)
KR (1) KR101803984B1 (fr)
CN (1) CN102741250B (fr)
AR (1) AR079495A1 (fr)
AU (1) AU2010333435B2 (fr)
BR (1) BR112012017205A2 (fr)
CA (1) CA2783726A1 (fr)
CO (1) CO6612245A2 (fr)
CR (1) CR20120319A (fr)
CY (1) CY1115843T1 (fr)
DK (1) DK2513107T3 (fr)
DO (1) DOP2012000165A (fr)
EA (1) EA023663B1 (fr)
ES (1) ES2514647T3 (fr)
GE (1) GEP20156241B (fr)
GT (1) GT201200171A (fr)
HR (1) HRP20140898T1 (fr)
IL (1) IL220327A (fr)
MA (1) MA33922B1 (fr)
MX (1) MX2012006969A (fr)
MY (1) MY158197A (fr)
NZ (1) NZ600260A (fr)
PH (1) PH12012501201A1 (fr)
PL (1) PL2513107T3 (fr)
PT (1) PT2513107E (fr)
RS (1) RS53579B1 (fr)
SG (1) SG181674A1 (fr)
SI (1) SI2513107T1 (fr)
SM (1) SMT201400158B (fr)
TN (1) TN2012000271A1 (fr)
TW (1) TWI485151B (fr)
UA (1) UA108487C2 (fr)
WO (1) WO2011072694A1 (fr)
ZA (1) ZA201204419B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
CA2800618C (fr) 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Composes heteroaryles et leurs procedes d'utilisation
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
CA2846758C (fr) * 2011-09-19 2017-09-12 F. Hoffmann-La Roche Ag Composes triazolopyridines en tant qu'inhibiteurs de pde10a
WO2013050527A1 (fr) 2011-10-05 2013-04-11 H. Lundbeck A/S Dérivés de quinazoline en tant qu'inhibiteurs de l'enzyme pde10a
TWI570124B (zh) 2011-12-21 2017-02-11 H 朗德貝克公司 作為pde10a酵素抑制劑的喹啉衍生物
KR20150021120A (ko) 2012-06-19 2015-02-27 선오비온 파마슈티컬스 인코포레이티드 헤테로아릴 화합물 및 이의 이용 방법
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
US9790203B2 (en) * 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
GB202319181D0 (en) * 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2004041258A2 (fr) 2002-10-30 2004-05-21 Neuro3D Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
CA2530114A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Derives de pyrrolo-dihydroisoquinoline comme inhibiteurs de pde10
KR20060030483A (ko) 2003-06-30 2006-04-10 알타나 파마 아게 Pde10 억제제로서 피롤로디히드로이소퀴놀린
WO2005012485A2 (fr) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
EP1755611A1 (fr) 2004-06-07 2007-02-28 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8492394B2 (en) * 2006-07-10 2013-07-23 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US8133897B2 (en) * 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
WO2010145668A1 (fr) 2009-06-19 2010-12-23 H. Lundbeck A/S Nouveau dérivé de phénylimidazole en tant qu'inhibiteur de l'enzyme pde10a
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物

Also Published As

Publication number Publication date
EP2513107B1 (fr) 2014-07-30
US20150290191A1 (en) 2015-10-15
US9096589B2 (en) 2015-08-04
US20120309714A1 (en) 2012-12-06
JP5901535B2 (ja) 2016-04-13
JP2013514284A (ja) 2013-04-25
PH12012501201A1 (en) 2017-01-27
EP2513107A1 (fr) 2012-10-24
EA201290516A1 (ru) 2013-01-30
DK2513107T3 (da) 2014-10-13
SG181674A1 (en) 2012-07-30
TWI485151B (zh) 2015-05-21
WO2011072694A1 (fr) 2011-06-23
PT2513107E (pt) 2014-10-22
TW201200515A (en) 2012-01-01
PL2513107T3 (pl) 2014-12-31
HK1177208A1 (en) 2013-08-16
GEP20156241B (en) 2015-02-10
CN102741250B (zh) 2015-10-14
KR101803984B1 (ko) 2017-12-01
AR079495A1 (es) 2012-02-01
TN2012000271A1 (en) 2013-12-12
US9669029B2 (en) 2017-06-06
CY1115843T1 (el) 2017-01-25
SI2513107T1 (sl) 2014-11-28
UA108487C2 (en) 2015-05-12
HRP20140898T1 (hr) 2014-11-07
BR112012017205A2 (pt) 2018-08-14
GT201200171A (es) 2015-01-16
ES2514647T3 (es) 2014-10-28
NZ600260A (en) 2014-08-29
MY158197A (en) 2016-09-15
RS53579B1 (sr) 2015-02-27
IL220327A (en) 2014-12-31
IL220327A0 (en) 2012-08-30
CR20120319A (es) 2012-08-16
CN102741250A (zh) 2012-10-17
EA023663B1 (ru) 2016-06-30
ZA201204419B (en) 2013-08-28
CA2783726A1 (fr) 2011-06-23
AU2010333435B2 (en) 2016-09-08
SMT201400158B (it) 2015-01-15
MX2012006969A (es) 2012-07-17
AU2010333435A1 (en) 2012-06-21
KR20120112460A (ko) 2012-10-11
CO6612245A2 (es) 2013-02-01
DOP2012000165A (es) 2012-12-15

Similar Documents

Publication Publication Date Title
MA33924B1 (fr) Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
UA112065C2 (uk) Похідні імідазолу як інгібітори ферменту pde10a
EA201290516A1 (ru) Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a
BR112015007731A2 (pt) pde9i com cadeia principal de imidazo pirazinona
MX2013012588A (es) Inhibidores de cinasa.
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
TH149187A (th) อนุพันธ์เฮเทอโรอะโรมาติกเอริลไตรอะโซลที่เป็นสารยับยั้งเอนไซม์ PDE10A (Heteroaromatic Aryl Triazole Derivatives As PDE10A Enzyme Inhibitors)
MX336915B (es) Derivados de imidazol como inhibidores de la enzima pde10a.
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
TN2014000288A1 (en) Pde9 inhibitors with imidazo triazinone backbone
TH136297A (th) อนุพันธ์เฮเทอโรอะโรมาติกฟีนิลอิมิดาโซล ที่เป็นสารยับยั้ง PDE10A เอนไซม์ (Heteroaromatic Phenylimidazole derivatives as PDE10A enzyme inhibitors)
CY1116689T1 (el) Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a